Most recent update: 1/2009 Hauke Walter Erlangen members Thomas - - PowerPoint PPT Presentation

▶
most recent update 1 2009 hauke walter erlangen members
SMART_READER_LITE
LIVE PREVIEW

Most recent update: 1/2009 Hauke Walter Erlangen members Thomas - - PowerPoint PPT Presentation

Nov 10, 2022 45 likes •155 views

Most recent update: 1/2009 Hauke Walter Erlangen members Thomas Berg Martin Obermeier Harm Mller Labor Berg Berlin Labor Fenner Hamburg Claudia Kcherer Rolf Kaiser RKI Berlin Uni Kln Hauke Walter Patrick Braun Klaus Korn Robert

slide-1
SLIDE 1

Most recent update: 1/2009 Hauke Walter Erlangen

slide-2
SLIDE 2

members

Rolf Kaiser Uni Köln Patrick Braun Robert Ehret PZB Aachen Thomas Berg Martin Obermeier Labor Berg Berlin Eva Wolf Labor Jajaprax München Martin Däumer IIG Kaiserslautern Harm Müller Labor Fenner Hamburg Martin Stürmer Uni Frankfurt Hauke Walter Klaus Korn NRC Uni Erlangen Josef Eberle MvP München Claudia Kücherer RKI Berlin

slide-3
SLIDE 3

RT

  • Major differences to other algorithms

– Resensitation effects – Interpretation for drug combinations in progress – HBV

slide-4
SLIDE 4

PR

  • Changes only for the new ones

– DRV

  • Weighted algorithm using scores for each mutation
  • 32I seems to be more relevant
  • Role of 82 mutations under discussion
  • Under discussion

– Weighting of 89V – Relevance of high numbers of secondary FPV mutations under discussion

– TPV

  • Several tries to remove polymorphisms from the algorithm

(e.g. by weighting)

  • Currently evaluating impact of actual algorithm on non-B

isolates

slide-5
SLIDE 5

gp41

slide-6
SLIDE 6

V3, gp160

  • No own algorithm

– Link to geno2pheno[coreceptor] will be implemented – High overlap of HIV-GRADE-TEAM and German coreceptor reference laboratories

  • German recommendations how to test CCR5

antagonists available at

– English version soon – www.viro.med.uni-erlangen.de

slide-7
SLIDE 7

IN

  • Implemented in 2008
  • Works fine
  • Phenotype is lacking

– Will be available at NRC within this year – Sequences can be send to MSD – Phenotype available e.g. at Monogram, SF, USA

slide-8
SLIDE 8

Phenotype and genotype

>451 >490 >125 >423 >35 >130 >264 >440 108 nd 379 406 2.3 139 1.6 18 5.5 2.4

0.1 1 10 100 1000 10000

AZT DDI D4T FTC Abacavir Tenofovir Nevirapin Delavirdin Efavirenz Etravirin Indinavir Saquinavir Nelfinavir Amprenavir Lopinavir Atazanavir Tipranavir Darunavir Max. a33251 Wildtyp

slide-9
SLIDE 9

Phenotype and genotype

1.1 nd 0.7 0.9 0.4 0.9 0.7 0.6 11 3.1 >35 0.2 0.2 1.4 3.8 0.4 >130 >264

0.1 1 10 100 1000 10000

AZT DDI D4T FTC Abacavir Tenofovir Nevirapin Delavirdin Efavirenz Etravirin Indinavir Saquinavir Nelfinavir Amprenavir Lopinavir Atazanavir Tipranavir Darunavir Max. a35757 Wildtyp

slide-10
SLIDE 10

Phenotype and genotype

>588 >451 nd >125 >140 >35 >130 >264 165 340 428 357 4.7 2.1 7.2 5 4.3 13

0.1 1 10 100 1000 10000

AZT DDI D4T FTC Abacavir Tenofovir Nevirapin Delavirdin Efavirenz Etravirin Indinavir Saquinavir Nelfinavir Amprenavir Lopinavir Atazanavir Tipranavir Darunavir Max. a35758 Wildtyp

slide-11
SLIDE 11

SUM up

  • Interpretation for PR, RT, IN and gp41
  • Coreceptor tropism will be implemented

– Interpretation according to g2p

  • Interpretation for NRTI combinations available

– Collect experiences and go on

  • HBV resistance interpretation available

– Additional escape mutations implemented

  • 2 do

– HIV-2 algorithm